Brief: Everest Medicines Says Licensing Partner Calliditas Therapeutics Announced U.S. FDA Approved Nefecon Delayed Release Capsules
21/12/2023 02:34
Dec 20 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES - LICENSING PARTNER CALLIDITAS
THERAPEUTICS
ANNOUNCED U.S. FDA APPROVED NEFECON DELAYED RELEASE CAPSULES
Source text for Eikon: ID:nPn46yBW5a
Further company coverage: 1952.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region